[A19-95] Avelumab (renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V

Last updated 02.03.2020

Project no.:
A19-95

Commission:
Commission awarded on 21.11.2019 by the Federal Joint Committee (G-BA).

Report type:
Dossier assessment

Status:
Commission completed

Department/Division:
Drug Assessment

Application field:
Cancer

Indication:

Treatment-naive adults with advanced renal cell carcinoma

Result of dossier assessment:

In favourable and intermediate risk profile: added benefit not proven; in poor risk profile: indication of non-quantifiable added benefit

Note:

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.

Contact

Info Service

Subscribe to daily updated information on projects, calls for tender, and events as well as our press releases.

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.